about the role of this protein in steroid and heme synthesis. We review the data on the structure and function of TSPO, as well as the recent results obtained using various genetic animal models. Taken together, these studies suggest that TSPO is a unique mitochondrial pharmacological target for diseases that involve increased mitochondrial activity, including steroidogenesis. Although there is no known mammalian species that lacks TSPO, it is likely that, because of the importance of this ancient protein in evolution and mitochondrial function, redundant mechanisms may exist to replace it under circumstances when it is removed.
biosynthesis has been widely and intensively studied using cell lines and animal models. It has been shown to be associated with cytosolic and mitochondrial proteins, part of a large multiprotein complex involved in mitochondrial cholesterol transport, the rate-limiting step in steroidogenesis. 4, [14] [15] [16] [17] In light of studies conducted over many years, there has been general agreement as to the structure and pharmacology of TSPO, the impact of TSPO drug ligands on in vitro and in vivo steroid production, and the therapeutic value of TSPO as anxiolytics in the brain and potentially in conditions of hypogonadism. However, recent reports of the effects of genetic depletion of TSPO have been controversial concerning the role of this protein in steroid and heme synthesis. [18] [19] [20] [21] We review the recent data on TSPO. Published cell and animal data suggest that lipid homeostasis, including esterified cholesterol involved in steroidogenesis, is dramatically affected by Tspo deletion/mutation. Changes in lipids and steroid production in response to pituitary peptide hormones vary between the fast responding adrenal cells, slow-responding testicular cells and hormone-independent brain cells. We consider that the new data discussed in the present review will reinforce the goals of exploring the biological roles of TSPO, as well as the potential therapeutic importance of targeting this mitochondrial protein pharmacologically.
| STRUCTURE AND FUNCTION OF TSPO IN STEROID HORMONE BIOSYNTHESIS
TSPO is an evolutionarily well-conserved OMM protein with five transmembrane domains. TSPO was previously known as the peripheral-type benzodiazepine receptor because it was identified as a binding site for the benzodiazepine diazepam. The protein has been shown to be present in particularly high levels in the steroidproducing cells of the adrenal and testis, to localise at the OMM 22 and to be regulated by hormones. 23, 24 Although specific amino acid substitution functional studies on the CARC motif of the nicotine acetylcholine receptor indicated slowed kinetics of cholesterol binding, it is not known whether CARC is functional in TSPO. 40 Studies of the effects of TSPO drug ligands in brain suggested pharmacological means by which neurosteroid formation might be regulated both in vitro and in vivo, 10, 26, 41 and also by which neuropsychiatric and neurodegenerative disorders, as well as neurotrauma, therefore might be treated. 24, 42 Indeed, TSPO, an OMM protein, is widely distributed in brain, dominantly in microglia cells (Figure 2 ), which play a major role in neuroinflammation. Induction of neurosteroid formation in the brain by TSPO drug ligands has been used to alleviate neuropsychiatric disease symptoms.
10
oxazin-2-amine), a TSPO/GABA A drug ligand with anxiolytic and anticonvulsant properties, is approved and marketed in France for the treatment of anxiety disorders, and studies are underway to treat peripheral nerve injuries and axonal neuropathies by regulating neurosteroid levels. [43] [44] [45] Moreover, a series of studies have supported a role for TSPO in inflammatory processes in peripheral tissues and the nervous system as a response to injury and disease; this role could be either passive, with TSPO being the result of increased mitochondrial membrane biogenesis occurring during microglia proliferation, or active, possibly through the regulation of reactive oxygen species (ROS) and local steroid production. 46, 47 Interestingly, the process of steroid formation, mediated by cytochrome P450s monooxygenases, is one of the drivers of ROS production in steroidogenic cells. 48, 49 Importantly, the stimulatory effects of TSPO drug ligands on adrenal, brain and gonadal steroids were relatively minor in normal (con- 
| GENETIC DELETION OF TSPO IN CELL MODELS
Despite studies conducted over the course of many years that have produced strong evidence for a highly significant role of TSPO in steroid hormone biosynthesis, recent studies based largely on genetic animal models have called this conclusion into question.
Knockdown of TSPO in tumour cell models has been achieved by homologous recombination, 55 antisense oligodeoxynucleotides 56 and antisense knockdown. 57 In each case, steroid biosynthesis in steroidogenic cells was reduced. Admittedly, however, it is technically challenging to be certain as to whether the effects seen on steroidogenesis in such studies were specifically a consequence of TSPO knockdown or reduced cell viability.
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A recent study reported no effect of TSPO knockdown in MA-10 cells. 20 In that study, no change in progesterone production was seen 48 hours after knockdown of TSPO expression by transfection with siRNAs. This was in striking contrast to previous reports showing a significant reduction of steroid production in the same cell line after TSPO knockdown using antisense oligodeoxynucleotides 56 or antisense knockdown. 57 As yet, the explanation for the difference in results is uncertain. In subsequent studies, it was suggested that the stimulation of progesterone formation in MA-10 cells by incubating the cells with the TSPO ligand PK 11195 may be unrelated to the ability of the ligand to bind TSPO. 20 This conclusion was reached as a result of studies reporting that the ligand was able to stimulate progesterone production in Tspo KO MA-10 cell lines generated via CRISPR/Cas9 technology. 20 Unfortunately, no PK 11195 binding data was provided, making it unclear how the conclusion could be reached that the TSPO deletion was complete and therefore that the effect of PK 11195 was 
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One of the main arguments used by Selvaraj and colleagues is that TSPO plays no role in steroidogenesis and the adrenal tumour H295R cells do not contain TSPO but produce steroids. 63 Indeed, this observation is cited as the "gold standard" to debunk the role of TSPO in steroid biosynthesis. However, previous studies reported that H295R cells do indeed express TSPO and that its levels were regulated by cAMP. 64 We confirmed this finding by immunoblot analysis (unpub- reduced mitochondrial respiration and increased mitochondrial oxidative stress. 68 However, the latter does not increase the ROS-generated macromolecular damage, 67 indicating that the effect of TSPO loss is 
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The question arises as to whether there is a compensatory mechanism capable of replacing TSPO function in regulating the permeability transition pore.
The role of TSPO in mediating mitochondrial cholesterol import for steroid hormone production has been questioned after a report on testis-specific Tspo KO using Amhr2-Cre. 18 Genetic KO of TSPO in the Leydig cells had no effect on testosterone production and it was concluded that "TSPO function is not essential for steroid hormone biosynthesis." Because we were unsuccessful in obtaining the generated mouse line used in that previous study, we generated the same Amhr2-Cre line of mice ourselves to produce testis-specific Tspo KO.
Although several attempts were made, we were unable to generate the Tspo cKO mouse that had been described 18 partly as a result of early embryonic lethality/adverse effects. However, all the mice with the cKO-genotypes had the same TSPO expression as the WT controls. 77 Additionally, we obtained an only small percentage of mice with such a cKO-genotype, which appears to represent survival from the "Cre-loxP" breeding system. After we reported the results, we realised that the two genes, Tspo and Amhr2-Cre, have strong genetic linkage with a genetic distance 18.1 cM, which makes the system difficult to be used for testis tissue-specific cKO. Moreover, the Amhr2 gene is expressed at early pre-implantation stages in the mouse. These observations suggest that the Tspo gene could be deleted at early preimplantational stages. We are continuing this work aiming to identify the specific role of TSPO in pre-implantation in relation to the identified genetic linkage. It is curious that Selvaraj and colleagues failed to have or to report the same problem using Amhr2-Cre. 18 To further examine the role of TSPO in steroidogeneses in a mouse model, we obtained a different Cre line, the Nr5a1(Sf-1)-Cre mouse, to generate the Tspo cKO mouse. 77 The Nr5a1 gene was shown to be specific to the testis, adrenal and brain, which are the steroidogenic tissues of interest. We were successful in obtaining mice with adrenal gland-specific Tspo cKO in which TSPO was almost completely removed in the cortex area. In the testes of these mice, TSPO was only partially depleted, as indicated by immunofluorescence staining, and there was no TSPO depletion in the brain. These patterns of TSPO depletion were found to correlate well with an increased presence of cholesterol-enriched lipid droplets in steroid synthesising cells and with reduced steroid production.
A human glial fibrillary acidic protein (hGFAP)-Cre-mediated TSPO KO mouse was generated to produce an astrocyte-and neural precursor-specific TSPO cKO. 78 Although TSPO −/− mice showed reduced astrogliosis and clinical symptoms in experimental autoimmune encephalomyelitis, accompanied by significant decreases in mRNA levels of cytokines TNFα and CXCL10, the GFAP was also found to be expressed in kidneys, testis, bone, cartilage, pancreas and liver. [79] [80] [81] [82] No data on brain steroid levels were presented, and no effects of TSPO drug ligands on the mutant animals were shown.
Mouse Tspo exon2/3 was deleted globally for the first time via C57BL/6 Cre deleter mice (the mouse used was not specified) to make a Tspo global KO (gKO) mouse. 83 The TSPO depletion was con- mitochondrial function that also had been observed in Drosophila. 67 In these studies, likely compensatory mechanisms were proposed, even though not specifically defined.
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Following the Tspo cKO using Amhr2-Cre, Tu, et al. from Selvaraj's group reported a second Tspo gKO using a global "Cre deleter": Ddx4-cre, where the data obtained showed that Tspo gKO was identical to the WT phenotype. 19 No difference was reported in the plasma level of steroid hormones, steroidogenic gene expression in the adrenal glands, the ultrastructural morphology of adrenal cortex and mitochondria, and lipid deposition in the adrenal cortex. A few genes related to immunity were reported to be differentially expressed by have no difference in heme biosynthesis, although low OCR, low ATP production and low proton leaking in fibroblasts were described, as previously reported in microglia. 21, 83 Unlike the data presented by Banati et al., 83 mice with TSPO depletion were not found to possess a low metabolic rate. The likely presence of an unknown compensatory mechanism was proposed to replace TSPO in steroidogenesis.
Another group used the protamine-Cre deleter to produce a Tspo gKO mouse line. 85 A normal Mendelian ratio from heterozygote (HE)×HE pairs was observed, as was normal morphology in the Tspo gKO mice. Interestingly, the RNA-sequencing data from lung tissues of Tspo gKO mice were found to have a transcriptomic profile identical to the WT mice. It is difficult to understand how TSPO depletion with a low metabolic rate would fail to be reflected in the gene expression profile of lungs. 83 Nevertheless, using immunoblot analyses, it was reported that TSPO was expressed at an extremely low level in brain, which is in contrast to that reported using immunofluorescence staining of TSPO, radioligand binding studies and positron electron tomography imaging. 83, [86] [87] [88] It is unfortunate that no attempt was made to use complementary approaches to validate their findings.
| CONCLUSIONS AND PERSPECTIVES
As noted earlier, it is clear from biochemical and pharmacological analyses that TSPO is a mitochondrial protein that can be targeted to increase steroid production in various states of reduced endogenous steroid synthesis and/or for hormone-independent steroid production, including neuropsychiatric disorders and hypogonadism.
With the exception of one study 20 formation. Although there is a tendency to equate the steroidogenic ability of the adrenal, gonadal and brain tissues, they are distinct, with the adrenal being a highly active and rapid responder (stress-response occurring within minutes), the testis a slower responder (hours to days) and the brain a constitutive responder (hormone-independent). These differences may also reflect differences between faster and slower lipid homeostasis and steroid formation. It is possible that TSPO functions somewhat differently in these three tissues. 92, 93 , although VDAC has a key role in this activity. These results suggest redundancy, with other proteins taking over VDAC function when VDAC is deleted.
This also is true of the IMM adenine nucleotide translocator 1 (ANT1), a critical component of mitochondrial oxidative phosphorylation. 94 Thus, Ant1 −/− mice were viable and fertile, with growth characteristics comparable to those of WT mice. 94 More recently, redundancy in the mitochondrial carrier system transporting small molecules between mitochondria and the cytoplasm was shown 95 and loss of one could be replaced by another gene or genetic network, depending on the methodology used. 96, 97 These findings suggest functional redundancies for key mitochondrial proteins including VDAC1, ANT1 and TSPO, ensuring that their functions are carried out.
The generation of animal models with genetic deletions of domains critical for TSPO function, such as the CRAC domain, and the use of other animals (eg, rats) to generate Tspo KOs would be of great use when addressing some among the many mechanistic issues involved in steroid formation, as well as other critical processes. However, the ultimate model is the human. No human has been identified lacking TSPO. However, the presence of rs6971 polymorphism (A147T)
on the TSPO gene results in an altered binding affinity of TSPO for specific ligands 98 and influences pregnenolone production in lymphomonocytes of healthy individuals. 99 Rs6971 also has been proposed to affect the hypothalamic-pituitary-adrenal axis, predisposing carriers to psychiatric disorders. 9, [99] [100] [101] Moreover, the presence of rs6971 was shown to affect the response of patients to anxiolytic TSPO drug ligands. 102 These observations raise critical questions of pathophysiological significance. For example, do carriers of rs6971 have differences in circulating steroid levels or do they respond in a different way to hormone stimuli or stress?
TSPO is a 3.5-billion-year-old protein. 17 Defining its structure, function and pharmacology will allow us to better understand the evolution of a protein and organelle, as well as processes (such as steroidogenesis) that are critical for life. We hope that this review has provided a critical evaluation of the state of the field, and helps to advance the science of TSPO. 
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